Search results
5 kwi 2022 · Rapid atrial fibrillation is treated with a beta-blocker or a nondihydropyridine calcium channel blocker such as diltiazem or verapamil, although beta-blocker is the option of choice if HF with reduced ejection fraction is involved, because of the pronounced negative-inotropic effect of nondihydropyridine CCBs. 29 Moreover, unlike beta-blockers ...
29 mar 2021 · The meta-analytic hazard ratio (HR) estimates and their 95% CIs comparing the relative risk of acute myocardial infarction, stroke, and hospitalization for heart failure between third-generation β-blockers (carvedilol and nebivolol) vs atenolol (propensity score matching, on-treatment).
1 sie 2004 · All patients with stable, mild, moderate and severe chronic heart failure from ischaemic or non-ischaemic cardiomyopathies and reduced left ventricular ejection fraction, in NYHA class II–IV, should be treated with β-blockers, unless there is a contraindication (class I, level of evidence A). 55,108 In patients with left ventricular systolic ...
10 kwi 2024 · Currently available β-blockers are a heterogeneous class of therapeutic agents and significant intra-class differences in individual drug selectivity, lipophilicity, and potential for partial agonism can inform the choice of β-blocker for a patient with one or more of a range of comorbid conditions 3.
13 gru 2006 · Celiprolol is a third generation beta blocker with a weak beta-2 agonist activity and weak alpha 2 blocker and direct smooth muscle relaxing properties. It reduces peripheral vascular resistance and has similar antihypertensive effects to metoprolol, propronalol, atenolol and pindolol.
22 sie 2023 · Objectives: Summarize the mechanism of action of the beta-blocker class of medications, including the difference between selective and non-selective agents. Identify the indications for beta-blocker therapy. Review the adverse events, contraindications, toxicities, and interactions of beta-blockers.
10 kwi 2024 · The new (2023) guideline from the European Society of Hypertension (ESH) includes β-blockers within five main classes of antihypertensive agents suitable for initiation of antihypertensive pharmacotherapy and for combination with other antihypertensive agents.
